Canadian biotech Aquinox Pharmaceuticals (NASDAQ: AQXP)
created quite the industry buzz last week when the company reported positive
mid-stage trial results for its bladder pain drug, AQX-1125.
In addition to meeting secondary endpoints, the LEADERSHIP
trial also demonstrated that a high proportion of patients (49%) achieved a
clinically meaningful improvement in pain (2 points or greater on an 11-point
NRS scale) as compared to placebo (39%).
“Consistently positive results from multiple secondary
endpoints have strengthened our confidence in further development of AQX-1125
for BPS/IC,” David Main, president and CEO of Aquinox stated in the news
release. “The encouraging effect of AQX-1125 observed on the primary endpoint
of reduction in pain together with several statistically significant secondary
endpoints, underscore the potential of AQX-1125 as a once daily, oral therapy
for this debilitating disease.”
Aquinox also provided a general business update, recapping
news from July when the company reported negative FLAGSHIP trial results for
AQX-1125 as treatment for chronic pulmonary disease (COPD). As such, the
company said it is not planning further development of AQX-1125 as a potential
treatment for COPD.
Aquinox instead is reallocating resources to the
prioritization of its activities to support possible future registration and
planned pivotal clinical trials with AQX-1125 for bladder pain
syndrome/interstitial cystitis (BPS/IC) and is deferring the initiation of its
phase 2 trial in chronic rhinosinusitis with nasal polyps.
Also on deck is approaching top line data in KINSHIP, a
phase 2 clinical trial to evaluate the safety and efficacy of AQX-1125 in
atopic dermatitis. Target enrollment in the KINSHIP trial was achieved in early
May 2015, and the company anticipates top line data from the trial in Q4 2015.
With Aquinox successfully advancing AQX-1125 for the
treatment of a disease affecting between 5 and 12 million Americans each year,
the company is aptly positioned to drive shareholder value – warranting a
second glance at the small company making big waves in the biotech market.
For more information visit www.aqxpharma.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
